Biomarkers /
CDK6
Overview
Cyclin-dependent kinase 4 (CDK6) is a gene that encodes a protein that is a member of the cyclin-dependent protein kinase family. The protein functions in the progression of the cell cycle at from G1 to S phase and the regulation of RB1. Fusions, missense, nonsense, and silent mutations are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.
CDK6 is altered in 0.91% of all cancers with lung adenocarcinoma, breast invasive ductal carcinoma, esophageal adenocarcinoma, pancreatic adenocarcinoma, and colon adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in CDK6 are CDK6 Amplification (0.57%), CDK6 Mutation (0.36%), CDK6 Loss (0.03%), CDK6 R220C (0.02%), and CDK6 E91* (0.01%) [3].
Clinical Trials
Significance of CDK6 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.